CHENGDU, China, Nov. 9 TianyinPharmaceutical, Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier ofmodernized traditional Chinese medicine ('TCM') based in Chengdu, China, todayannounced that management will hold a conference call to discuss its fiscal2010 first quarter results at 10:30 a.m. ET on Friday, November 13, 2009.Financial results will be released prior to the market open on that day. APowerPoint presentation which provides further details on the quarter and therecently announced Sichuan Jiangchuan Pharmaceutical Co. Ltd. joint venturewill accompany management's discussion and can be accessed via the webcastlink.
A replay will be available through November 21, 2009 and can be accessedby dialing (800) 406-7325 (U.S.), (303) 590-3030 (Int'l), Pin Code 4182573.
Webcast Access Information
Access Link: http://www.talkpoint.com/viewer/starthere.asp?pres=128645
You will need to have the Windows Media Player on your desktop. For a freedownload:http://www.microsoft.com/windows/windowsmedia/en/download/default.asp .
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized traditional Chinesemedicine in China. It was established in 1994 and acquired by the currentmanagement team in August 2003. It has a comprehensive product portfolio of39 products, 22 of which are listed in the highly selective National MedicineCatalog of the National Medical Insurance program. Tianyin owns and operatesthree GMP manufacturing facilities and an R&D platform supported by leadingChinese academic institutions. The company has a pipeline of 17pharmaceutical products pending approval. Tianyin has an extensive nationwidedistribution network throughout China with a sales force of 720 salespeople.Tianyin is headquartered in Chengdu, Sichuan Province with three manufacturingfacilities and a total of 1,365 employees. For more information about Tianyin,please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.Call Access Information: (877) 941-2321 from within the United States (480) 629-9714 if calling internationally Conference ID is 4182573
SOURCE Tianyin Pharmaceutical, Co., Inc.